ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today...
Clinical operations, regulatory affairs, technical expertise, and corporate leadership additions support advancing gene therapy pipeline for cardiovascular diseasesBOSTON, Sept. 30,...
No safety concerns or dose limiting toxicities observed SCY-247 was able to achieve target exposures at doses lower than our...
~ Topline results from the EXPLORE-OSA trial are anticipated in 1Q 2026 ~ RADNOR, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE)...
GARDNER, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and...
Spring® Scope delivers the largest working channel of any flexible single-use cystoscope, enhancing visualization and patient comfortSOUTH SAN FRANCISCO, Calif.,...
DES MOINES, Iowa, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Stride Autism Centers, a leading provider of center-based early intervention ABA...
The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being...
SEATTLE, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to...
-- AjD Represents an Area of Significant Unmet Need; No U.S. Food and Drug Administration (FDA)-Approved Therapies Available -- --...
BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company...
Carlsbad, CA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or “the Company”) today announced the...
Based on previously reported positive Phase 1 results, Kynexis is advancing KYN-5356, a first-in-class KAT-II inhibitor, into a Phase 2...
Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting...
NEUMÜNSTER, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tilray Medical a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX:...
Additional time enables LAVA Therapeutics to address potential liabilities and confirm net cash to be delivered to Shareholders. LAVA Therapeutics...
WAYNE, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...
Focal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option Focal One Robotic HIFU Patient Story...
Canada’s Largest Charity Dedicated to Lung Health Responds to the Launch of a Canada Post StrikeTORONTO, Sept. 30, 2025 (GLOBE...
RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics, a regenerative medicine company developing biologic drug therapies...